Either suppression of Kras signaling or restoration of Trp53 function is sufficient to cause regression of lung tumors in mice, supporting the possibility that Kras and Trp53 are therapeutic targets in NSCLC [5]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.